Neurosurgical Approach to the Patient with Glioblastoma

Podolsky-Gondim, Guilherme Gozzoli; Oliveira, Ricardo Santos de; CarlottiJr, Carlos Gilberto; Colli, Benedicto Oscar

doi:10.1007/978-3-030-69170-7_3

Cited by 1 publication

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, despite the identification of ZIKV as a GBM oncolytic agent, to date no clinical trials have been undertaken to further investigate this. Except for a single reported case, no experimental protocols have been proposed in the last six years [21,22]. Nevertheless, ZIKV can be directly used in its natural form with minimal adverse effects in adults, and without widespread immunity in the population.…”

Section: Discussionmentioning

confidence: 99%

Oncolytic Effect of Zika Virus in Neuroendocrine Pancreatic Tumors: New Perspectives for Therapeutic Approaches

Cocco,

Carcione,

Miceli

et al. 2023

IJMS

View full text Add to dashboard Cite

Pancreatic cancer (PCa) is the fifth leading cause of cancer mortality. Recently, our group and others have demonstrated the oncolytic activity of the Zika virus (ZIKV) against glioblastoma. The peculiar features of this virus offer the opportunity to use an agent already tested in vivo through natural transmission, with minimal effects on adults, to specifically target a tumor such as glioblastoma. This remarkable specificity prompted us to explore the potential use of ZIKV oncolytic action against other tumor types. In particular, we focused on the subgroup of pancreatic tumors with a neuroendocrine origin known as neuroendocrine tumors (NETs). We found that ZIKV exerts its oncolytic activity by specifically infecting NET cells, leading to growth inhibition and cell death. We also assessed whether the oncolytic action could be extended to pancreatic tumors different from NETs. However, as expected, the viral specificity is limited to NETs and is not applicable to adenocarcinoma tumors, indicating a narrow spectrum of action for this virus. These findings support the potential use of ZIKV in therapeutic approaches not only in glioblastoma, but also against other tumors, such as neuroendocrine pancreatic tumors.

show abstract

Section: Discussionmentioning

confidence: 99%